196 related articles for article (PubMed ID: 20872958)
21. A retrospective analysis of treatment outcomes in 45 patients with cardiac light-chain amyloidosis: a single-center experience in Japan.
Fuchida SI; Ide D; Taminishi-Katsuragawa Y; Suga T; Matsui-Maegawa S; Maruyama N; Iwamura Y; Kitamura Y; Okawa Y; Okano A; Hatsuse M; Murakami S; Shimazaki C
Int J Hematol; 2020 Jun; 111(6):803-811. PubMed ID: 32020505
[TBL] [Abstract][Full Text] [Related]
22. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.
Sanchorawala V; Wright DG; Rosenzweig M; Finn KT; Fennessey S; Zeldis JB; Skinner M; Seldin DC
Blood; 2007 Jan; 109(2):492-6. PubMed ID: 16960148
[TBL] [Abstract][Full Text] [Related]
23. Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T.
Dispenzieri A; Gertz MA; Saenger A; Kumar SK; Lacy MQ; Buadi FK; Dingli D; Leung N; Zeldenrust S; Hayman SR; Kapoor P; Grogan M; Hwa L; Russell SJ; Go RS; Rajkumar SV; Kyle RA; Jaffe A
Am J Hematol; 2015 Jun; 90(6):524-8. PubMed ID: 25753178
[TBL] [Abstract][Full Text] [Related]
24. Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study.
Daniels LB; Laughlin GA; Clopton P; Maisel AS; Barrett-Connor E
J Am Coll Cardiol; 2008 Aug; 52(6):450-9. PubMed ID: 18672166
[TBL] [Abstract][Full Text] [Related]
25. Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement.
Bézard M; Oghina S; Vitiello D; Kharoubi M; Kordeli E; Galat A; Zaroui A; Guendouz S; Gilles F; Shourick J; Hamon D; Audard V; Teiger E; Poullot E; Molinier-Frenkel V; Lemonnier F; Agbulut O; Le Bras F; Damy T
PLoS One; 2021; 16(9):e0257189. PubMed ID: 34525116
[TBL] [Abstract][Full Text] [Related]
26. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
[TBL] [Abstract][Full Text] [Related]
27. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.
Palladini G; Campana C; Klersy C; Balduini A; Vadacca G; Perfetti V; Perlini S; Obici L; Ascari E; d'Eril GM; Moratti R; Merlini G
Circulation; 2003 May; 107(19):2440-5. PubMed ID: 12719281
[TBL] [Abstract][Full Text] [Related]
28. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis.
Lilleness B; Ruberg FL; Mussinelli R; Doros G; Sanchorawala V
Blood; 2019 Jan; 133(3):215-223. PubMed ID: 30333122
[TBL] [Abstract][Full Text] [Related]
29. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.
Palladini G; Barassi A; Klersy C; Pacciolla R; Milani P; Sarais G; Perlini S; Albertini R; Russo P; Foli A; Bragotti LZ; Obici L; Moratti R; Melzi d'Eril GV; Merlini G
Blood; 2010 Nov; 116(18):3426-30. PubMed ID: 20644111
[TBL] [Abstract][Full Text] [Related]
30. sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T.
Emdin M; Aimo A; Vergaro G; Bayes-Genis A; Lupón J; Latini R; Meessen J; Anand IS; Cohn JN; Gravning J; Gullestad L; Broch K; Ueland T; Nymo SH; Brunner-La Rocca HP; de Boer RA; Gaggin HK; Ripoli A; Passino C; Januzzi JL
J Am Coll Cardiol; 2018 Nov; 72(19):2309-2320. PubMed ID: 30384887
[TBL] [Abstract][Full Text] [Related]
31. [Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
Charliński G; Wiater E; Jedrzejczak WW
Pol Merkur Lekarski; 2012 Apr; 32(190):217-20. PubMed ID: 22708276
[TBL] [Abstract][Full Text] [Related]
32. Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis.
Merlini G; Lousada I; Ando Y; Dispenzieri A; Gertz MA; Grogan M; Maurer MS; Sanchorawala V; Wechalekar A; Palladini G; Comenzo RL
Leukemia; 2016 Oct; 30(10):1979-1986. PubMed ID: 27416985
[TBL] [Abstract][Full Text] [Related]
33. [Current treatment of AL amyloidosis].
Desport E; Moumas E; Abraham J; Delbès S; Lacotte-Thierry L; Touchard G; Fermand JP; Bridoux F; Jaccard A
Nephrol Ther; 2011 Nov; 7(6):467-73. PubMed ID: 21497573
[TBL] [Abstract][Full Text] [Related]
34. Improvement of risk assessment in systemic light-chain amyloidosis using human placental growth factor.
Kristen AV; Rinn J; Hegenbart U; Lindenmaier D; Merkle C; Röcken C; Hardt S; Giannitsis E; Katus HA
Clin Res Cardiol; 2015 Mar; 104(3):250-7. PubMed ID: 25331161
[TBL] [Abstract][Full Text] [Related]
35. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.
Palladini G; Milani P; Foli A; Obici L; Lavatelli F; Nuvolone M; Caccialanza R; Perlini S; Merlini G
Haematologica; 2014 Apr; 99(4):743-50. PubMed ID: 24213149
[TBL] [Abstract][Full Text] [Related]
36. Takotsubo cardiomyopathy has a unique cardiac biomarker profile: NT-proBNP/myoglobin and NT-proBNP/troponin T ratios for the differential diagnosis of acute coronary syndromes and stress induced cardiomyopathy.
Fröhlich GM; Schoch B; Schmid F; Keller P; Sudano I; Lüscher TF; Noll G; Ruschitzka F; Enseleit F
Int J Cardiol; 2012 Feb; 154(3):328-32. PubMed ID: 22044675
[TBL] [Abstract][Full Text] [Related]
37. Utility of B-Type Natriuretic Peptide for Detecting Cardiac Involvement in Immunoglobulin Amyloidosis.
Kimishima Y; Yoshihisa A; Kiko T; Yokokawa T; Miyata-Tatsumi M; Misaka T; Oikawa M; Kobayashi A; Takeishi Y
Int Heart J; 2019 Sep; 60(5):1106-1112. PubMed ID: 31484874
[TBL] [Abstract][Full Text] [Related]
38. Serial measurement of N-terminal pro-B-type natriuretic peptide and cardiac troponin T for cardiovascular disease risk assessment in the Multi-Ethnic Study of Atherosclerosis (MESA).
Daniels LB; Clopton P; deFilippi CR; Sanchez OA; Bahrami H; Lima JA; Tracy RP; Siscovick D; Bertoni AG; Greenland P; Cushman M; Maisel AS; Criqui MH
Am Heart J; 2015 Dec; 170(6):1170-83. PubMed ID: 26678639
[TBL] [Abstract][Full Text] [Related]
39. Fatal cardiac and renal allograft rejection with lenalidomide therapy for light-chain amyloidosis.
Meyers DE; Adu-Gyamfi B; Segura AM; Buja LM; Mallidi HR; Frazier OH; Rice L
Am J Transplant; 2013 Oct; 13(10):2730-3. PubMed ID: 23914832
[TBL] [Abstract][Full Text] [Related]
40. Light-chain amyloidosis: SCT, novel agents and beyond.
Rosenzweig M; Giralt S; Landau H
Bone Marrow Transplant; 2013 Aug; 48(8):1022-7. PubMed ID: 23103675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
